ZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate Seborrheic Dermatitis

NCT07404033 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Seborrheic Dermatitis

Interventions

DRUG: ZYG24002 0.5%
DRUG: ZYG24002 0.75%
DRUG: ZYG24002 1%
DRUG: ZYG24002 Placebo

Sponsor

Sinomune Pharmaceutical Co., Ltd